Temozolomide-induced biliary ductopenia: a case report

BACKGROUND: Temozolomide is an alkylating agent used along with concurrent radiation therapy in the treatment of glioblastoma. The primary adverse effect of temozolomide is bone marrow suppression with resulting cytopenias. There have been reported cases of temozolomide-induced hepatotoxicity, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Balakrishnan, Asha, Ledford, Robert, Jaglal, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743416/
https://www.ncbi.nlm.nih.gov/pubmed/26846183
http://dx.doi.org/10.1186/s13256-016-0804-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743416/
https://www.ncbi.nlm.nih.gov/pubmed/26846183
http://dx.doi.org/10.1186/s13256-016-0804-z

Ejemplares similares